Wilshire Pharmaceuticals Recalls Meclizine HCl Tablets for Dissolution Failures
Wilshire Pharmaceuticals is recalling 3,592 bottles of Meclizine HCl 25 mg tablets because they failed dissolution specifications. The affected product was distributed in Florida and Texas.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, and the source text does not report any illnesses or injuries, fitting the criteria for a moderate severity recall involving potential but not confirmed adverse health consequences.
Plain-English summary
Wilshire Pharmaceuticals, Inc. is recalling 3,592 bottles of Meclizine HCl Tablets, USP, 25 mg (NDC 52536-133-01). The recall was initiated because the product failed to meet dissolution specifications. The affected lots are 18030329, 18030330, and 18030331, all with an expiration date of 03/2021.
The recalled product was distributed in Florida and Texas. Meclizine HCl is a prescription medication used to treat motion sickness and dizziness. The product is manufactured in India for Wilshire Pharmaceuticals, Inc., located in Atlanta, Georgia.
Consumers who have this product should stop using it and contact their healthcare provider or pharmacist for further instructions. The FDA has classified this recall as Class II, which means the use of, or exposure to, the violative product may cause temporary or medically reversible adverse health consequences.
The recalled product
- Product
- Meclizine HCl Tablets, USP, 25 mg, 100 Tablets bottles, Rx Only, Mfd. for: Wilshire Pharmaceuticals, Inc., Atlanta, GA 30328, Product of India, NDC 52536-133-01
- Manufacturer
- Wilshire Pharmaceuticals Inc
- Category
- Drug — Prescription Medication
- Hazard
- Affected units
- 35,928
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lot #: 18030329
- 18030330
- 18030331
- Exp 03/2021.
Distribution
Part of a larger recall action
This product is one of 2 recalled by Wilshire Pharmaceuticals Inc under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same manufacturer · Wilshire Pharmaceuticals Inc
See all →- ModerateWilshire Pharmaceuticals Recalls Meclizine HCl Tablets for Dissolution Failures
FDA (Drugs) · 2021-02-24
Same hazard · dissolution failure
See all →- ModerateApotex Recalls Paxil Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-02
- ModerateMylan Recalls Acamprosate Calcium Tablets Due to Dissolution Failure
FDA (Drugs) · 2026-08-26
- ModerateChlorthalidone 25mg tablets failed dissolution specifications in two batches
FDA (Drugs) · 2026-06-24
- ModerateNiacin extended-release tablets failed dissolution testing at 24 hours
FDA (Drugs) · 2026-06-17
- ModerateMinocycline extended-release tablets failed dissolution testing during stability analysis
FDA (Drugs) · 2026-06-17